Nonin’s partnership with EnsoData aims to bring accessible sleep testing and diagnosis to all audiences, including patients with limited access to care.

RT’s Three Key Takeaways

  1. Nonin Medical and EnsoData have partnered to improve access to home sleep apnea testing by combining Nonin’s WristOx2® Model 3150 device with EnsoData’s FDA-cleared EnsoSleep PPG AI software.
  2. This collaboration aims to address the high prevalence of obstructive sleep apnea (OSA), affecting nearly 1 billion people worldwide, by providing an affordable, accurate, and accessible diagnostic solution for underserved populations.
  3. The integration allows EnsoSleep’s AI to analyze data from Nonin’s wrist-worn devices, enabling efficient sleep staging and event detection to support sleep labs and clinicians in diagnosing OSA.

EnsoData, a pioneer in healthcare AI, and Nonin Medical, a leader in pulse oximetry devices, announce a partnership to address the underserved and undiagnosed sleep apnea patient population with a collaborative home sleep apnea testing approach. The partnership will combine the recently FDA-cleared EnsoSleep PPG software as a medical device (SaMD) algorithm with Nonin’s WristOx2 Model 3150 reusable wrist-worn device, offering sleep labs an affordable solution to test for sleep apnea at home.

Obstructive sleep apnea (OSA) is an increasingly common condition that if left untreated, exacerbates many other cardiac, respiratory, metabolic, neurodegenerative, and mental health problems. It affects almost 1 billion people globally, including 425 million who have moderate to severe OSA. Severe OSA is characterized by 30 or more apnea events per hour – which manifests in a cycle where patients stop breathing, on average, once every other minute. This partnership aims to address this patient population by delivering a collaborative solution to help improve overall population health metrics.

Nonin’s WristOx2® Model 3150 devices deliver fast, accurate oxygen saturation and pulse rate readings in challenging conditions, including low perfusion and in motion by using sensors that provide continuous SpO2 monitoring and data recording.1

“Customers who choose Nonin, choose durability, accuracy and equity,” said John Hastings, CEO of Nonin Medical. “Combining our class-leading noninvasive monitoring products with EnsoData’s innovative AI platform will increase patient access to quality diagnosis in the significantly under-served field of sleep apnea.”

EnsoSleep PPG is interoperable with compatible FDA-cleared pulse oximetry devices, which now includes the Nonin WristOx2® Model 3150, allowing the AI to analyze collected data and provide sleep staging and event detection analysis to sleep labs and clinicians using Nonin devices.

“This partnership is an important step toward increasing patient access to quality sleep care,” said Justin Mortara, CEO of EnsoData. “As a trusted manufacturer of high-quality pulse oximetry solutions, Nonin’s devices provide more innovative hardware options for our customers to use in conjunction with EnsoSleep PPG. We are excited to launch this collaboration and continue to grow the EnsoData network of sleep medicine partnerships.”